v3.25.2
Stock Based Compensation - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Stock compensation expense capitalized to inventory   $ 300,000 $ 0 $ 500,000 $ 0  
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount   $ 53,900,000   $ 53,900,000    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition       2 years 7 months 6 days    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number   17,271,990   17,271,990   15,161,180
Restricted common stock, vesting in equal monthly installments       10 years    
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage       25.00%    
Aggregate Intrinsic Value, Exercised       $ 5,900,000 3,400,000  
Fair Value of Shares Vested       $ 12,200,000 $ 9,900,000  
Common stock reserved for future awards or option grants   28,192,494   28,192,494   23,338,272
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value       $ 8.6 $ 4.52  
Restricted Stock Units [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number   1,382   1,382   2,763
Equity Incentive Plan 2016 and 2020 [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized   25,737,116   25,737,116    
Equity Incentive Plan 2018 [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized   6,634,333   6,634,333    
Common Stock [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share purchased under employee stock purchase plan       111,918 43,679  
Equity Incentive Plans [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Description In September 2018, ARS Pharma adopted the 2018 Equity Incentive Plan. As a result of the Merger, on November 8, 2022 ARS Pharma assumed Silverback’s 2016 and 2020 Equity Incentive Plans, and Employee Stock Purchase Plan (“ESPP”). There were 111,918 shares and 43,679 shares of common stock purchased under the ESPP during the six months ended June 30, 2025 and 2024, respectively.          
Equity Incentive Plans [Member] | Equity Incentive Plan 2016 and 2020 [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number   13,033,358   13,033,358    
Common stock reserved for future awards or option grants   7,765,139   7,765,139    
Equity Incentive Plans [Member] | Equity Incentive Plan 2018 [Member]            
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number   4,240,014   4,240,014    
Common stock reserved for future awards or option grants   297,345   297,345